About Us

GEUS Technology

Aniling owns the GEUS technology, which unifies genetic and epigenetic sequencing and provides end-to-end solutions for the right treatment decisions in oncology. Based on GEUS, Aniling is developing a set of products for cancer diagnostic.


The first Aniling product is the most comprehensive Chronic Lymphocytic Leukemia Next Generation Sequencing diagnostics panel. The GEUS-CLL delivers accurate staging and treatment decisions. Aniling S.L. provides the GEUS-CLL diagnostic test as a service to other laboratories and hospitals.

Latest News

World Cancer Day

World Cancer Day 2023

In 2 days, we will mark World Cancer Day. World Cancer Day is a global uniting initiative led by the Union for International Cancer Control (UICC). It aims to promote awareness …

RETOS 2017

Retos Colaboration 2017 project completion

Aniling completes the Retos Colaboración project with the development of a genetic and epigenetic test (GEUS-LB®) for the early detection of colorectal cancer  in a blood sample. The Aniling -led project uses patented GEUS …